Viking Therapeutics price target raised to $115 from $37 at Raymond James

Raymond James raised the firm’s price target on Viking Therapeutics to $115 from $37 and keeps an Outperform rating on the shares as the firm says that 14.7% unadjusted change from baseline body weight in the highest dose arm of the VENTURE trial suggests that VK2735 is “meaningfully more potent than tirzepatide and likely as potent as retatrutide.” The firm is increasing its view of the odds of success of VK2735 to 80% and now modeling peak sales of about $10B, the analyst tells investors.